JP7599727B2 - マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット - Google Patents

マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット Download PDF

Info

Publication number
JP7599727B2
JP7599727B2 JP2022519804A JP2022519804A JP7599727B2 JP 7599727 B2 JP7599727 B2 JP 7599727B2 JP 2022519804 A JP2022519804 A JP 2022519804A JP 2022519804 A JP2022519804 A JP 2022519804A JP 7599727 B2 JP7599727 B2 JP 7599727B2
Authority
JP
Japan
Prior art keywords
therapeutic
compound
diagnostic
dextran
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550174A (ja
JP2022550174A5 (cg-RX-API-DMAC10.html
Inventor
エイ. ラルフ、デイビッド
アーノルド、ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Navidea Biopharmaceuticals Inc
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of JP2022550174A publication Critical patent/JP2022550174A/ja
Publication of JP2022550174A5 publication Critical patent/JP2022550174A5/ja
Application granted granted Critical
Publication of JP7599727B2 publication Critical patent/JP7599727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2022519804A 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット Active JP7599727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962908136P 2019-09-30 2019-09-30
US62/908,136 2019-09-30
PCT/US2020/053604 WO2021067479A1 (en) 2019-09-30 2020-09-30 Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands

Publications (3)

Publication Number Publication Date
JP2022550174A JP2022550174A (ja) 2022-11-30
JP2022550174A5 JP2022550174A5 (cg-RX-API-DMAC10.html) 2023-09-28
JP7599727B2 true JP7599727B2 (ja) 2024-12-16

Family

ID=75337533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519804A Active JP7599727B2 (ja) 2019-09-30 2020-09-30 マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット

Country Status (7)

Country Link
US (1) US20210145989A1 (cg-RX-API-DMAC10.html)
EP (1) EP4021459A4 (cg-RX-API-DMAC10.html)
JP (1) JP7599727B2 (cg-RX-API-DMAC10.html)
CN (1) CN115151264B (cg-RX-API-DMAC10.html)
CA (1) CA3155675A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022003699A (cg-RX-API-DMAC10.html)
WO (1) WO2021067479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
EP4472643A1 (en) * 2022-02-04 2024-12-11 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
CN114894698B (zh) * 2022-04-15 2023-02-03 广东省第二人民医院(广东省卫生应急医院) MDSCs在再生障碍性贫血诊断和/或分型中的应用
US20240024491A1 (en) * 2022-07-13 2024-01-25 Navidea Biopharmaceuticals, Inc. Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169883A1 (en) 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
JP2006098265A (ja) 2004-09-30 2006-04-13 Shimadzu Corp 試料の解析方法
JP2016527252A (ja) 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ,インコーポレーテッド Cd206発現細胞関連障害を診断および処置するための組成物、方法およびキット

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624046A (en) * 1982-01-04 1986-11-25 Fairchild Camera & Instrument Corp. Oxide isolation process for standard RAM/PROM and lateral PNP cell RAM
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
JP3582234B2 (ja) * 1996-05-20 2004-10-27 ニプロ株式会社 IgA腎症特異的フィブロネクチン断片、その検出方法およびキット
US6409990B1 (en) * 1999-05-14 2002-06-25 The Regents Of The University Of California Macromolecular carrier for drug and diagnostic agent delivery
EP1501522A4 (en) * 2002-05-06 2007-12-05 Univ Utah Res Found PRE-BLOCKING WITH NON-HA GAGS INCREASES THE EFFECTIVENESS OF HA-CONJUGATED CANCER
WO2005086639A2 (en) * 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20080182816A1 (en) * 2006-02-23 2008-07-31 Tam Joemy C Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
WO2018068060A1 (en) * 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
US20190021608A1 (en) * 2017-05-19 2019-01-24 Navidea Biopharmaceuticals, Inc. CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in Humans
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169883A1 (en) 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
JP2006098265A (ja) 2004-09-30 2006-04-13 Shimadzu Corp 試料の解析方法
JP2016527252A (ja) 2013-07-22 2016-09-08 ナビディア・バイオファーマシューティカルズ,インコーポレーテッド Cd206発現細胞関連障害を診断および処置するための組成物、方法およびキット

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Zhengtao QIN et al.,"Molecular Imaging of the Glomerulus via Mesangial Cell Uptake of Radiolabeled Tilmanocept",Journal of Nuclear Medicine,2019年02月22日,Vol.60,No.9,p.1325-1332,DOI: 10.2967/jnumed.118.223727
Zohreh VARASTEH et al.,"Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept",EJNMMI Research,2017年,Vol.7,40,p.1-9,DOI: 10.1186/s13550-017-0287-y

Also Published As

Publication number Publication date
JP2022550174A (ja) 2022-11-30
CN115151264A (zh) 2022-10-04
WO2021067479A1 (en) 2021-04-08
EP4021459A4 (en) 2023-09-27
EP4021459A1 (en) 2022-07-06
MX2022003699A (es) 2022-07-13
US20210145989A1 (en) 2021-05-20
CA3155675A1 (en) 2021-04-08
CN115151264B (zh) 2024-03-12

Similar Documents

Publication Publication Date Title
US20210145989A1 (en) Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
ES2788865T3 (es) Conjugados farmacéuticos de nanopartículas
US11559591B2 (en) Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
EP3448436A1 (en) Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CA2955438A1 (en) Dextran conjugates for targeting macrophages and other mannose binding c-type lectin receptor expressing cells
JP7805170B2 (ja) 前立腺特異的膜抗原(psma)リガンド及びその使用
US12178829B2 (en) Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
JP2016528299A (ja) ビタミンb12および内因子を含む組成物およびその使用方法
AU2021327392A1 (en) Compositions and methods for targeting tumor-associated macrophages
WO2020055455A1 (en) Targeted nanoparticles for diagnosing, detecting, and treating cancer
CN111447955A (zh) 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途
US20210052639A1 (en) Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
ES2784182T3 (es) Composiciones y métodos para inducir la apoptosis
US20230302041A1 (en) Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
JP2022514463A (ja) 抗がん剤の送達のための立体錯体
US20250382392A1 (en) Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
WO2023076220A1 (en) Conjugates having antifouling nanoparticles and methods of use
JP2025523813A (ja) ペイロードをcd206発現細胞に対して標的化する分解可能なジスルフィド/炭酸塩リンカーを有するマンノシル化アミンデキストラン薬物送達ビヒクル
BR122024008143A2 (pt) Uso de conjugados de nanopartículas para tratamento de tumor cerebral

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241127

R150 Certificate of patent or registration of utility model

Ref document number: 7599727

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150